News

In this second segment of an interview with Managed Healthcare Executive about this presentation about aesthetic dermatology at the 2025 Fall Clinical Dermatology Conference, Mark S.Nestor, M.D., Ph.D., discussed botulinum toxin injections, the effects that injections into the glalbella can have on depression and differing molecular potencies of the different brands of botulinum toxin.

In this first segment from an interview with Managed Healthcare Executive about his presentation about trends in aesthetic dermatology, the 2025 Fall Clinical Dermatology Conference in Las Vegas, Mark S. Nestor, M.D., Ph.D., talks about the shift away from hyaluronic acid to collagen stimulators, such as poly-L-lactic acid.

Here’s what you missed this week on Managed Healthcare Executive.

Mona Shahriari, M.D., dermatologist at Central Connecticut Dermatology and an associate clinical professor at Yale School of Medicine discusses the highlights of her session called ‘Seeing Clearly: A Visual Guide to Diagnosing Prurigo Nodularis in Skin of Color.’

Determining a biologic's duration of use to treat pediatric atopic dermatitis has several factors, according to Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego.

Expensive, newer therapies and a lack of pediatric data are roadblocks to advancing treatment for pediatric atopic dermatitis, according to Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego.

Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego, gives an overview of his session at the 2025 Fall Clinical Dermatology Conference.

Lawrence Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children’s Hospital, San Diego, discusses why his clinic has shifted towards earlier atopic dermatitis treatment for patients.

Shawn Kwatra, M.D., reveals new OX40 ligand therapies for atopic dermatitis, promising new hope for patients at the Fall Clinical Dermatology meeting.

Employer health premiums rose significantly this year, impacting healthcare costs and insurance access. A KFF survey reveals trends in coverage and employee contributions.

Study participants who used the mPATH-Lung program were 60% more likely to undergo lung cancer screening, than particpants who did not use the program.

A greater understanding of the association between multiple sclerosis (MS) and the oral microbiome may lead to less invasive dialogistic markers and novel treatment options for patients, according to this recent study by researchers at the University of Iowa Health Care.

Rebyota improves quality of life for patients with recurrent C. difficile (C. diff) infections, according to two analyses of real-world data presented at IDWeek 2025.

New findings reveal aflibercept 8 mg enhances vision and extends injection intervals for nAMD and DME patients, reducing treatment burden significantly.

Experts reveal strategies to improve breast cancer screening and outcomes for underserved communities, addressing disparities during Breast Cancer Awareness Month.

Socioeconomic factors are a key risk factor for Type 2 diabetes, but a new analysis says the same is not true when it comes to Type 1 diabetes.

New research reveals AREDS vitamins do not slow geographic atrophy progression in AMD, urging patients to explore FDA-approved treatments instead.

Gazyva is the first and only anti-CD20 monoclonal antibody approved to treat kidney inflammation associated with lupus.

Here’s what you missed this week on Managed Healthcare Executive.

At the American Academy of Ophthalmology meeting, Andrew G. Lee, M.D., explained that El Nino and La Nina weather patterns — worsened by climate change — can worsen eye conditions such as dry eye, cataracts, infections and UV-related damage while also influencing disease outbreaks and access to care.

A study using AAO's IRIS Registry demonstrates Eylea HD 8 mg improves vision in treatment-naive patients with wet age-related macular degeneration or diabetic macular edema with previously treated patients extending dosing intervals two weeks.

A phase 3 trial of Hernexeos (zongertinib) as a first-line treatment for patients with lung cancer tumors with HER2 mutations is underway.

Biosimilars enhance arthritis treatment access, with rising adoption among women and long-term patients, revealing key prescribing patterns in Turkey.

Retina specialists pushed for health awareness, professional independence and industry diversity at this morning’s American Academy of Ophthalmology session.

Daniel Henick, M.D., an ophthalmology resident at Yale New Haven Medical Center, is raising awareness for pickleball injuries by encouraging players to wear protective eye gear during games.

New findings reveal significant geographic disparities in Medicare access, costs and quality, impacting millions of beneficiaries across the U.S.